Provided by Tiger Fintech (Singapore) Pte. Ltd.

Xenon Pharmaceuticals

37.98
+1.464.00%
Post-market: 37.980.00000.00%16:10 EDT
Volume:694.14K
Turnover:26.11M
Market Cap:2.93B
PE:-10.71
High:38.06
Open:36.74
Low:36.15
Close:36.52
52wk High:46.00
52wk Low:26.74
Shares:77.11M
Float Shares:71.60M
Volume Ratio:0.92
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5448
EPS(LYR):-3.0083
ROE:-37.65%
ROA:-25.52%
PB:4.62
PE(LYR):-12.63

Loading ...

Company Profile

Company Name:
Xenon Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
1996
Employees:
322
Office Location:
200-3650 Gilmore Way,Burnaby,British Columbia,Canada
Zip Code:
V5G 4W8
Fax:
604 484 3450
Introduction:
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

Directors

Name
Position
Ian C. Mortimer
President and Chief Executive Officer and Director and interim Chief Financial Officer and Principal Accounting Officer
Dawn Svoronos
Chair and Lead Independent Director
Elizabeth Garofalo
Director
Gary Patou
Director
Gillian Cannon
Director
Justin Gover
Director
Patrick Machado
Director
Steven Gannon
Director

Shareholders

Name
Position
Ian C. Mortimer
President and Chief Executive Officer and Director and interim Chief Financial Officer and Principal Accounting Officer
Andrea DiFabio
Chief Legal Officer and Corporate Secretary
Christopher Kenney
Chief Medical Officer